358 related articles for article (PubMed ID: 32034074)
1. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
Figlin RA; Tannir NM; Uzzo RG; Tykodi SS; Chen DYT; Master V; Kapoor A; Vaena D; Lowrance W; Bratslavsky G; DeBenedette M; Gamble A; Plachco A; Norris MS; Horvatinovich J; Tcherepanova IY; Nicolette CA; Wood CG;
Clin Cancer Res; 2020 May; 26(10):2327-2336. PubMed ID: 32034074
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Mai HX; Mei GH; Zhao FL; Li BT; Tang YY; Zhang B; Xu XJ; Chen LJ
J Cancer Res Ther; 2018 Jun; 14(Supplement):S427-S432. PubMed ID: 29970701
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
5. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
7. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].
Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
9. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.
Lemoine FM; Cherai M; Giverne C; Dimitri D; Rosenzwajg M; Trebeden-Negre H; Chaput N; Barrou B; Thioun N; Gattegnio B; Selles F; Six A; Azar N; Lotz JP; Buzyn A; Sibony M; Delcourt A; Boyer O; Herson S; Klatzmann D; Lacave R
Int J Oncol; 2009 Sep; 35(3):569-81. PubMed ID: 19639177
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
11. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
[TBL] [Abstract][Full Text] [Related]
12. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Amin A; Dudek AZ; Logan TF; Lance RS; Holzbeierlein JM; Knox JJ; Master VA; Pal SK; Miller WH; Karsh LI; Tcherepanova IY; DeBenedette MA; Williams WL; Plessinger DC; Nicolette CA; Figlin RA
J Immunother Cancer; 2015; 3():14. PubMed ID: 25901286
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
Boorjian S
Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
17. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
[TBL] [Abstract][Full Text] [Related]
19. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract][Full Text] [Related]
20. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
